Overcoming the challenges of RNAi-based therapy: an interview with James Hamilton

J Hamilton currently serves as vice president of Clinical Development at Arrowhead Pharmaceuticals, Inc. (CA, USA), where he is responsible for clinical strategy, clinical trial design, implementation and execution. In this role, he managed the ARC-520, ARC-521 and ARC-AAT global programs. Previously, he was medical director and head of Corporate Development at Arrowhead. He led Arrowhead's acquisition of the Novartis RNAi assets and led Arrowhead's $670 million cardiovascular deal with Amgen (CA, USA). He earned an MD and MBA at The Ohio State University (USA) and is a licensed physician with board certification in emergency medicine. J Hamilton speaks to Hannah Makin, commissioning editor.